Cargando…

Estimating long-term clinical effectiveness and cost-effectiveness of HPV 16/18 vaccine in China

BACKGROUND: Human papillomavirus (HPV) 16 and 18 are the two most common HPV oncogenic types that can be prevented by vaccination. This study aimed at assessing the cost-effectiveness of 3 doses of the bivalent HPV vaccine in rural and urban settings in China. METHODS: A Markov model was adapted to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Qian, Liu, Yi-Jun, Hu, Shang-Ying, Zhao, Fang-Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5097411/ https://www.ncbi.nlm.nih.gov/pubmed/27814703 http://dx.doi.org/10.1186/s12885-016-2893-x

Ejemplares similares

Effect of vaccination age on cost-effectiveness of human papillomavirus vaccination against cervical cancer in China
por: Liu, Yi-Jun, et al.
Publicado: (2016)

Bivalent Human Papillomavirus (HPV) Vaccine Effectiveness Correlates With Phylogenetic Distance From HPV Vaccine Types 16 and 18
por: Bogaards, Johannes A, et al.
Publicado: (2019)

Long-Term immunopersistence and safety of the Escherichia coli-produced HPV-16/18 bivalent vaccine in Chinese adolescent girls
por: Yao, Xingmei, et al.
Publicado: (2022)

Assessment of the effectiveness of HPV16/18 infection referred for colposcopy in cervical cancer screening in Northwest of China
por: Zhang, Qian, et al.
Publicado: (2017)

Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial
por: Einstein, Mark H, et al.
Publicado: (2014)

Construction and immune effect of an HPV16/18/58 trivalent therapeutic adenovirus vector vaccine
por: Wan, Bing, et al.
Publicado: (2022)

The levels of anti-HPV16/18 and anti-HPV31/33/35/45/52/58 antibodies among AS04-adjuvanted HPV16/18 vaccinated and non-vaccinated Ugandan girls aged 10–16 years
por: Nakalembe, Miriam, et al.
Publicado: (2014)

Design of a Synthetic Long Peptide Vaccine Targeting HPV-16 and -18 Using Immunoinformatic Methods
por: Tîrziu, Alexandru, et al.
Publicado: (2023)

Prevalence of HPV 16 and HPV 18 Lineages in Galicia, Spain
por: Pérez, Sonia, et al.
Publicado: (2014)

Human papillomavirus (HPV) vaccination for the prevention of HPV 16/18 induced cervical cancer and its precursors
por: Damm, Oliver, et al.
Publicado: (2009)

Prevalence of HPV 16 and 18 and attitudes toward HPV vaccination trials in patients with cervical cancer in Mali
por: Téguété, Ibrahima, et al.
Publicado: (2017)

Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain
por: De La Fuente, Jesús, et al.
Publicado: (2019)

Genetic Diversity of HPV 16 and HPV 18 Based on Partial Long Control Region in Iranian Women
por: Mobini Kesheh, Mina, et al.
Publicado: (2022)

Methylation estimates the risk of precancer in HPV-infected women with discrepant results between cytology and HPV16/18 genotyping
por: Hernández-López, Rubí, et al.
Publicado: (2019)

Cervarix(™): a vaccine for the prevention of HPV 16, 18-associated cervical cancer
por: Monie, Archana, et al.
Publicado: (2008)

In silico design of a multi-epitope vaccine against HPV16/18
por: Sanami, Samira, et al.
Publicado: (2022)

Safety and immunogenicity of a bivalent HPV16/18 vaccine in Chinese females
por: Shi, Li-Wei, et al.
Publicado: (2023)

A novel trivalent HPV 16/18/58 vaccine with anti-HPV 16 and 18 neutralizing antibody responses comparable to those induced by the Gardasil quadrivalent vaccine in rhesus macaque model
por: Yin, Fei, et al.
Publicado: (2017)

Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK
por: Kohli, M, et al.
Publicado: (2007)

Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria
por: Boiron, L., et al.
Publicado: (2016)

Effectiveness of the AS04‐adjuvanted HPV‐16/18 vaccine in reducing oropharyngeal HPV infections in young females—Results from a community‐randomized trial
por: Lehtinen, Matti, et al.
Publicado: (2019)

Changes in HPV16/18 Prevalence among Unvaccinated Women with Cervical Intraepithelial Neoplasia in Japan: Assessment of Herd Effects following the HPV Vaccination Program
por: Onuki, Mamiko, et al.
Publicado: (2022)

The effectiveness of HPV16 and HPV18 genotyping and cytology with different thresholds for the triage of human papillomavirus-based screening on self-collected samples
por: Song, Fangbin, et al.
Publicado: (2020)

Is It Time to Genotype Beyond HPV16 and HPV18 for Cervical Cancer Screening?
por: Chua, Brandon Wen Bing, et al.
Publicado: (2022)

HPV16 and HPV18 Genome Structure, Expression, and Post-Transcriptional Regulation
por: Yu, Lulu, et al.
Publicado: (2022)

Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India
por: Diaz, M, et al.
Publicado: (2008)

Prevalence of cervical infection with HPV type 16 and 18 in Vietnam: implications for vaccine campaign
por: Vu, Lan TH, et al.
Publicado: (2013)

Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types
por: Kavanagh, K, et al.
Publicado: (2014)

HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial
por: van Poelgeest, Mariette I E, et al.
Publicado: (2013)

Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada
por: Kohli, Michele, et al.
Publicado: (2012)

Efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in Chinese women aged 18–25 years: event‐triggered analysis of a randomized controlled trial
por: Zhu, Feng‐cai, et al.
Publicado: (2016)

The correlation of HPV16 and HPV18 with local vaginal immunity after the treatment of cervical intraepithelial neoplasia
por: Mu, Lin, et al.
Publicado: (2020)

An Updated Analysis of the Impact of HPV Vaccination Based on Long-term Effectiveness in the Netherlands
por: Luttjeboer, Jos, et al.
Publicado: (2023)

Long‐term effectiveness of HPV vaccination against HPV infection in young Japanese women: Real‐world data
por: Kurosawa, Megumi, et al.
Publicado: (2022)

Absence of HPV 16 and 18 DNA in breast cancer.
por: Wrede, D., et al.
Publicado: (1992)

Monitoring HPV16/18 immunisation in England and elsewhere
por: Franceschi, S
Publicado: (2010)

Significantly Reduced Genoprevalence of Vaccine-Type HPV-16/18 Infections among Vaccinated Compared to Non-Vaccinated Young Women 5.5 Years after a Bivalent HPV-16/18 Vaccine (Cervarix®) Pilot Project in Uganda
por: Kumakech, Edward, et al.
Publicado: (2016)

Triage of HPV-positive women in Norway using cytology, HPV16/18 genotyping and HPV persistence
por: Arbyn, Marc, et al.
Publicado: (2020)

The Risk Stratification for Cervical Cancer and Precursors of Domestic HPV Testing With HPV 16/18 Genotyping in Women With NILM Cytology in CentralChina: A Cohort Study
por: Xu, Hui-Fang, et al.
Publicado: (2021)

Strong reduction in prevalence of HPV16/18 and closely related HPV types in sexually active adolescent women following the introduction of HPV vaccination in Argentina
por: González, Joaquín Víctor, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_99ajo1cl4lii6q4ttmkr8mg5m7